Tiba Aynechi

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California.

Norwest Venture Partners is a venture capital division of Norwest Partners founded in 1961. The firm is headquartered in Palo Alto, California with additional offices in Mumbai and Herzliya.

Cianna Medical, Inc. manufactures and marketing equipment for the treatment of early-stage breast cancer in women. The firm’s products include SAVI, a breast brachytherapy applicator used for the delivery of radiation after lumpectomy surgery; and SAVI SCOUT, a surgical guidance system that uses real-time audible and visual indicators to give surgeons a precise way to target tissue during lumpectomy and excisional biopsy procedures. The company was founded in 2007 and is headquartered in Aliso Viejo, CA.

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden.

Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA.

MDLIVE, Inc. operates as a telehealth provider of online and on-demand healthcare delivery services and software. Its cloud-based virtual medical office software platform enables patients, medical professionals, and plan administrators to collaborate through voice, video, email, and mobile devices; and allows payers and providers to collect and share clinical data from patient medical records, lab results, and in-home biometric devices for real-time risk assessments, wellness advice, diagnosis, and treatment. The company was founded by Randy Parker and Steven Victor Gurland in 2009 and is headquartered in Sunrise, FL.

Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA.

MBX Biosciences, Inc. operates as a preclinical-stage biotech company. It creates therapies to treat rare endocrine diseases. The company was founded by Peter Kent Hawryluk and Timothy Knickerbocker and is headquartered in Carmel, IN.

Allievex Corp. operates as a biotechnology company. It develops therapies for the treatment of rare pediatric neurodegenerative diseases. The company was founded by Thomas P. Mathers and Eric H. Zanelli and is headquartered in Marblehead, MA.

Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation.

Rezo Therapeutics, Inc. is a drug discovery company based in San Francisco, CA. The company's mission is to revolutionize traditional drug development by integrating proteomics, genetics, structural biology, chemistry, artificial intelligence, and machine learning to create maps of molecular disease networks. Rezo's initial focus is on oncology, but they plan to explore additional therapeutic areas through collaborations and partnerships. The company was founded by Natalia Jura, Kevan Shokat, Nevan Krogan, Sourav Bandyopadhyay, Norbert W. Bischofberger, and George A. Scangos, with Nevan Krogan serving as CEO since incorporation.